Another site for the Magnetic Resonance Outcome (MRO) study in Europe

Overseen by Professor Dixon and Dr Kulkarni, the Western General Hospital in Edinburgh is joining the effort to evaluate the ClearCoast™ MRI system as another European site. The study was launched in June 2021 with its first site in Frankfurt am Main headed by Professor Dr. Marc Thill.

The ClearCoast™ MRI system enables the intraoperative assessment of the surgical margin during breast-conserving surgery. This makes it possible to identify positive margins even without radiological expertise so that any necessary follow-up resection can take place immediately, i.e. as part of the initial surgery. This often means the patient does not have to undergo a second operation. With current methods, it is unavoidable that 15–30% of cases will require follow-up surgery for additional resection or even a mastectomy.¹ The advantage of the ClearCoast™ MRI system: The surrounding healthy tissue can be retained to the greatest possible degree. The objective of the study is to lower the rate of subsequent surgeries.

The manufacturer of the ClearCoast™ system and the sponsor of the trial is ClearCut Medical Ltd. from Israel. pfm medical ag holds a stake in ClearCut Medical and is the exclusive distribution partner in Europe.

For more information about the ClearCoast™ MRI system, please click here.

Sources:
1 Benjamin W. Maloney, David M. McClatchy, Brian W. Pogue, Keith D. Paulsen, Wendy A. Wells, Richard, J. Barth, Jr.“Review of methods for intraoperative margin detection for breast conserving surgery,” J. Biomed. Opt. 23(10), 100901 (2018), doi: 10.1117/1.JBO.23.10.100901